Transdiagnostic variations in impulsivity and compulsivity in obsessive-compulsive disorder and gambling disorder correlate with effective connectivity in cortical-striatal-thalamic-cortical circuits.
Adolescent
Adult
Brain
/ physiopathology
Brain Mapping
Female
Gambling
/ physiopathology
Humans
Image Interpretation, Computer-Assisted
Impulsive Behavior
/ physiology
Magnetic Resonance Imaging
Male
Middle Aged
Neural Pathways
/ physiopathology
Obsessive-Compulsive Disorder
/ physiopathology
Phenotype
Young Adult
Compulsivity
DCM
Disinhibition
GD
Impulsivity
OCD
Journal
NeuroImage
ISSN: 1095-9572
Titre abrégé: Neuroimage
Pays: United States
ID NLM: 9215515
Informations de publication
Date de publication:
15 11 2019
15 11 2019
Historique:
received:
08
03
2019
revised:
24
07
2019
accepted:
02
08
2019
pubmed:
6
8
2019
medline:
12
9
2020
entrez:
6
8
2019
Statut:
ppublish
Résumé
Individual differences in impulsivity and compulsivity is thought to underlie vulnerability to a broad range of disorders and are closely tied to cortical-striatal-thalamic-cortical function. However, whether impulsivity and compulsivity in clinical disorders is continuous with the healthy population and explains cortical-striatal-thalamic-cortical dysfunction across different disorders remains unclear. Here, we characterized the relationship between cortical-striatal-thalamic-cortical effective connectivity, estimated using dynamic causal modelling of resting-state functional magnetic resonance imaging data, and dimensional phenotypes of impulsivity and compulsivity in two symptomatically distinct but phenotypically related disorders, obsessive-compulsive disorder and gambling disorder. 487 online participants provided data for modelling of dimensional phenotypes. These data were combined with 34 obsessive-compulsive disorder patients, 22 gambling disorder patients, and 39 healthy controls, who underwent functional magnetic resonance imaging. Three core dimensions were identified: disinhibition, impulsivity, and compulsivity. Patients' scores on these dimensions were continuously distributed with the healthy participants, supporting a continuum model of psychopathology. Across all participants, higher disinhibition correlated with lower bottom-up connectivity in the dorsal circuit and greater bottom-up connectivity in the ventral circuit, and higher compulsivity correlated with lower bottom-up connectivity in the dorsal circuit. In patients, higher clinical severity was also linked to lower bottom-up connectivity in the dorsal circuit, but these findings were independent of phenotypic variation, demonstrating convergence towards behaviourally and clinically relevant changes in brain dynamics. Effective connectivity did not differ as a function of traditional diagnostic labels and only weak associations were observed for functional connectivity measures. Together, our results demonstrate that cortical-striatal-thalamic-cortical dysfunction across obsessive-compulsive disorder and gambling disorder may be better characterized by dimensional phenotypes than diagnostic comparisons, supporting investigation of quantitative liability phenotypes.
Identifiants
pubmed: 31382045
pii: S1053-8119(19)30658-5
doi: 10.1016/j.neuroimage.2019.116070
pmc: PMC6721865
mid: EMS84191
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
116070Subventions
Organisme : Wellcome Trust
ID : 110049
Pays : United Kingdom
Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.
Références
Braz J Psychiatry. 2007 Jun;29(2):107-17
pubmed: 17639253
Am J Psychiatry. 2010 Jul;167(7):748-51
pubmed: 20595427
Eur Neuropsychopharmacol. 2016 May;26(5):828-40
pubmed: 26774661
Biol Psychiatry. 2012 Apr 15;71(8):741-8
pubmed: 22342105
Nat Neurosci. 2005 Feb;8(2):147-8
pubmed: 15643429
Psychol Methods. 2001 Dec;6(4):430-50
pubmed: 11778682
Neuropsychopharmacology. 2010 Jan;35(1):4-26
pubmed: 19812543
Neuroimage. 2015 Feb 1;106:1-14
pubmed: 25463471
J Behav Addict. 2015 Dec;4(4):263-72
pubmed: 26690621
PLoS One. 2012;7(3):e30909
pubmed: 22479305
Philos Trans R Soc Lond B Biol Sci. 2008 Oct 12;363(1507):3125-35
pubmed: 18640910
Neuroimage. 2017 Jul 1;154:174-187
pubmed: 28302591
Nat Commun. 2018 Apr 12;9(1):1428
pubmed: 29651138
PLoS One. 2013 Sep 02;8(9):e74353
pubmed: 24023940
Neurosci Lett. 2014 Nov 7;583:120-5
pubmed: 25238959
Clin Psychol Rev. 2011 Aug;31(6):923-33
pubmed: 21664339
PLoS One. 2013 Dec 19;8(12):e84565
pubmed: 24367675
Nat Neurosci. 2013 Apr;16(4):386-7
pubmed: 23434914
Nat Rev Neurosci. 2007 Sep;8(9):725-32
pubmed: 17704814
Neuroimage Clin. 2013 Mar 05;2:385-93
pubmed: 24179792
J Clin Psychol. 2007 Sep;63(9):851-9
pubmed: 17674398
Psychol Assess. 2002 Dec;14(4):485-96
pubmed: 12501574
Neuron. 2011 Feb 24;69(4):680-94
pubmed: 21338879
Neuroimage. 2003 Aug;19(4):1273-302
pubmed: 12948688
CNS Spectr. 2014 Feb;19(1):69-89
pubmed: 24512640
Neurosci Biobehav Rev. 2004 Apr;28(2):123-41
pubmed: 15172761
PLoS One. 2017 Sep 7;12(9):e0182939
pubmed: 28880888
Curr Opin Neurobiol. 2013 Aug;23(4):655-9
pubmed: 23375671
Biol Psychiatry. 2013 Feb 15;73(4):321-8
pubmed: 23200527
Neuroimage. 2015 May 15;112:278-287
pubmed: 25770990
BMC Med. 2013 May 14;11:126
pubmed: 23672542
Nature. 2012 Sep 20;489(7416):391-399
pubmed: 22996553
CNS Spectr. 2018 Feb;23(1):51-58
pubmed: 28487007
Biol Psychiatry. 2012 Apr 15;71(8):749-57
pubmed: 22336565
J Chem Neuroanat. 2003 Dec;26(4):317-30
pubmed: 14729134
Elife. 2016 Mar 01;5:
pubmed: 26928075
Neurosci Biobehav Rev. 2018 Apr;87:151-160
pubmed: 29410103
Drugs. 2011 May 7;71(7):827-40
pubmed: 21568361
Neuron. 2015 Aug 19;87(4):716-32
pubmed: 26291157
Arch Gen Psychiatry. 2009 Nov;66(11):1189-200
pubmed: 19884607
Neurosci Biobehav Rev. 2013 Nov;37(9 Pt A):1946-54
pubmed: 23438892
Trends Cogn Sci. 2012 Jan;16(1):81-91
pubmed: 22155014
Am J Psychiatry. 2011 Jul;168(7):718-26
pubmed: 21572165
J Anxiety Disord. 2007;21(1):105-17
pubmed: 16647833
Neuroimage. 2018 May 1;171:415-436
pubmed: 29278773
Neuroimage Clin. 2017 Dec 05;17:704-716
pubmed: 29264112
Hum Brain Mapp. 2009 Feb;30(2):392-402
pubmed: 18095285
Neuroimage. 2015 Jan 15;105:536-51
pubmed: 25462692
Drug Alcohol Depend. 2014 Dec 1;145:77-86
pubmed: 25448081
Genes Brain Behav. 2017 Sep;16(7):647-663
pubmed: 28421658
J Neurosci. 2016 Mar 16;36(11):3115-26
pubmed: 26985024
Behav Res Ther. 2005 Nov;43(11):1527-42
pubmed: 16299894
J Anxiety Disord. 2008;22(3):475-84
pubmed: 17481852
Clin Psychol Rev. 2011 Nov;31(7):1198-208
pubmed: 21871853
Brain Connect. 2011;1(1):13-36
pubmed: 22432952
Am J Psychiatry. 2015 Mar 1;172(3):284-93
pubmed: 25526600
Biol Psychiatry. 2014 Apr 15;75(8):631-8
pubmed: 23510580
Neurosci Biobehav Rev. 2008;32(4):777-810
pubmed: 18295884
CNS Spectr. 2019 Aug;24(4):426-440
pubmed: 30458896
Med Image Anal. 2008 Feb;12(1):26-41
pubmed: 17659998
Clin Psychol Rev. 2011 Aug;31(6):965-82
pubmed: 21733491
Neuroimage. 2013 Jan 1;64:240-56
pubmed: 22926292
Nat Neurosci. 2005 Nov;8(11):1481-9
pubmed: 16251991
Neuroimage. 2016 Mar;128:413-431
pubmed: 26569570
Neuroimage. 2015 May 15;112:267-277
pubmed: 25770991
Psychol Med. 2018 Apr;48(5):810-821
pubmed: 28805173
Netw Neurosci. 2017;1(3):222-241
pubmed: 29400357
PLoS One. 2012;7(9):e45938
pubmed: 23029329
Neuroimage. 2012 Mar;60(1):623-32
pubmed: 22233733
Neuroimage. 2010 Feb 15;49(4):3099-109
pubmed: 19914382
Neurosci Biobehav Rev. 2018 Jan;84:204-217
pubmed: 29203423
Neuropsychopharmacology. 2010 Feb;35(3):591-604
pubmed: 19940844
Psychol Assess. 2007 Mar;19(1):107-18
pubmed: 17371126
Hum Brain Mapp. 2017 Jan;38(1):109-119
pubmed: 27548880
Neuroimage. 2014 Jul 1;94:396-407
pubmed: 24345387